Ligand Panretin Labeling Should Reflect Kaposi's Response Rate Of 15%-19%
Executive Summary
FDA-calculated beneficial response rates of 15%-19% for Ligand's Panretin gel in Kaposi's sarcoma are more representative of the drug's true efficacy than response rates presented by the company, FDA's Oncologic Drugs Advisory Committee concluded Nov. 16. The committee voted unanimously to include FDA's response rates in product labeling.